Key Highlights

  • AIMD shares trading down 14.27% today to $0.625, below the $0.80 low of its 52-week range as of Oct. 21.
  • Market Capitalization was about $6.65 million as of Oct. 21, according to a market data page.
  • Cash and equivalents were $1,422,912 at June 30, with a net loss of $4,594,731 for the second quarter.
  • Convertible notes payable total $11.0 million, all held by ASE.
  • Ainos completed delivery of 1,400 AI Nose systems under a $2.1 million, three-year agreement.

No Fresh Announcement Found as Ainos Slides Below $1

Ainos (NASDAQ:AIMD) shares are trading down 14.27% today at $0.625, and no company-specific announcement explaining the drop was identified. The only company release found for today highlights that its scent dataset has passed 3 billion real-world chemical data points. A market data snapshot from Oct. 21 showed a 52-week range of $0.80 to $4.02, so the stock now sits below that floor.

Ainos develops AI Nose, a sensing platform that converts scent signals into machine-readable Smell ID data, now aimed at industrial uses such as semiconductor Manufacturing and robotics. It also develops VELDONA, a low-dose oral interferon platform. The company's 2025 Revenue was about $124,157, according to a market data page, and the same source showed a trailing net loss near $14.5 million.

Semiconductor Deliveries and VELDONA Licensing Headline Recent Updates

In late September, Ainos said it had finished delivering 1,400 AI Nose systems to ASE under a $2.1 million, three-year agreement. It also advanced the platform into commercial deployment in front-end semiconductor manufacturing earlier in the month. Separately, three Japanese patents were granted for its electronic nose in robotics in early September.

The company completed the VELDONA technology transfer, which triggered a $600,000 initial license payment. It also signed a VELDONA license with BioPhoenix carrying a potential aggregate value of $10 million. Those announcements came before the latest decline, and none of them addresses today's move directly. Ainos also reported second-quarter results on Aug. 3, which the company's filings cover in detail.

Going Concern Warning and ASE-Held Convertible Notes Frame the Balance Sheet

Ainos reported a second-quarter net loss of $4,594,731, compared with $4,084,990 a year earlier. The six-month net loss was $7,054,531, versus $7,371,012 in the same period of 2025. Cash and equivalents rose to $1,422,912 at June 30 from $417,353 at the end of 2025, but the quarterly filing states that substantial doubt exists about the company's ability to continue as a going concern.

Convertible notes payable total $11.0 million, all held by ASE, with $2.0 million due in March 2027 and $9.0 million due in May 2027. ASE also lent about NT$90 million, roughly $2.8 million, in March 2026, and part of that Loan was extended to July 31, 2027. As of Aug. 3, about 7.38 million shares were outstanding.

Sub-$1 Pricing and a Reverse Split History Keep Funding and Share Count in Focus

The filing describes earlier 1-for-5 reverse stock splits, the latest effective June 30, 2025, carried out to meet Nasdaq's $1.00 minimum bid price requirement. With shares now below $1, the share count and funding path remain closely watched, although the filing does not describe a current deficiency notice. The next Quarterly Report should show how the cash position, ASE note maturities and license payments have developed.